170 related articles for article (PubMed ID: 38664521)
1. Immunotherapy and drug sensitivity predictive roles of a novel prognostic model in hepatocellular carcinoma.
Gao X; Ren X; Wang F; Ren X; Liu M; Cui G; Liu X
Sci Rep; 2024 Apr; 14(1):9509. PubMed ID: 38664521
[TBL] [Abstract][Full Text] [Related]
2. A novel mitochondrial unfolded protein response-related risk signature to predict prognosis, immunotherapy and sorafenib sensitivity in hepatocellular carcinoma.
Zhang S; Guo H; Wang H; Liu X; Wang M; Liu X; Fan Y; Tan K
Apoptosis; 2024 Jun; 29(5-6):768-784. PubMed ID: 38493408
[TBL] [Abstract][Full Text] [Related]
3. Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment.
Zhang FP; Huang YP; Luo WX; Deng WY; Liu CQ; Xu LB; Liu C
World J Gastroenterol; 2020 Jan; 26(2):134-153. PubMed ID: 31969776
[TBL] [Abstract][Full Text] [Related]
4. An immune-related gene signature for predicting survival and immunotherapy efficacy in hepatocellular carcinoma.
Dai Y; Qiang W; Lin K; Gui Y; Lan X; Wang D
Cancer Immunol Immunother; 2021 Apr; 70(4):967-979. PubMed ID: 33089373
[TBL] [Abstract][Full Text] [Related]
5. Identification of prognostic markers for hepatocellular carcinoma based on the epithelial-mesenchymal transition-related gene BIRC5.
Xu R; Lin L; Zhang B; Wang J; Zhao F; Liu X; Li Y; Li Y
BMC Cancer; 2021 Jun; 21(1):687. PubMed ID: 34112092
[TBL] [Abstract][Full Text] [Related]
6. The sorafenib resistance-related gene signature predicts prognosis and indicates immune activity in hepatocellular carcinoma.
Luo T; Chen X; Pan W; Zhang S; Huang J
Cell Cycle; 2024 Jan; 23(2):150-168. PubMed ID: 38444181
[TBL] [Abstract][Full Text] [Related]
7. Identification of prognostic biomarkers for patients with hepatocellular carcinoma after hepatectomy.
Wang X; Liao X; Yang C; Huang K; Yu T; Yu L; Han C; Zhu G; Zeng X; Liu Z; Zhou X; Qin W; Su H; Ye X; Peng T
Oncol Rep; 2019 Mar; 41(3):1586-1602. PubMed ID: 30628708
[TBL] [Abstract][Full Text] [Related]
8. Construction of a novel immune-related lncRNA signature and its potential to predict the immune status of patients with hepatocellular carcinoma.
Deng M; Lin JB; Zhao RC; Li SH; Lin WP; Zou JW; Wei W; Guo RP
BMC Cancer; 2021 Dec; 21(1):1347. PubMed ID: 34923955
[TBL] [Abstract][Full Text] [Related]
9. Identification and validation of redox-immune based prognostic signature for hepatocellular carcinoma.
Tu K; Li J; Mo H; Xian Y; Xu Q; Xiao X
Int J Med Sci; 2021; 18(9):2030-2041. PubMed ID: 33850474
[TBL] [Abstract][Full Text] [Related]
10. System Analysis of ROS-Related Genes in the Prognosis, Immune Infiltration, and Drug Sensitivity in Hepatocellular Carcinoma.
Xu JH; Guan YJ; Qiu ZD; Zhang X; Zi LL; Zhou Y; Chen C; Yu J; Zhang YC; Wang WX
Oxid Med Cell Longev; 2021; 2021():6485871. PubMed ID: 34795841
[TBL] [Abstract][Full Text] [Related]
11. Identification of immune-related lncRNA signature for predicting immune checkpoint blockade and prognosis in hepatocellular carcinoma.
Xu Q; Wang Y; Huang W
Int Immunopharmacol; 2021 Mar; 92():107333. PubMed ID: 33486322
[TBL] [Abstract][Full Text] [Related]
12. Identification and validation of ADME genes as prognosis and therapy markers for hepatocellular carcinoma patients.
Wang J; Han K; Zhang C; Chen X; Li Y; Zhu L; Luo T
Biosci Rep; 2021 May; 41(5):. PubMed ID: 33988674
[TBL] [Abstract][Full Text] [Related]
13. Identification of Prognostic Genes in the Tumor Microenvironment of Hepatocellular Carcinoma.
Xiang S; Li J; Shen J; Zhao Y; Wu X; Li M; Yang X; Kaboli PJ; Du F; Zheng Y; Wen Q; Cho CH; Yi T; Xiao Z
Front Immunol; 2021; 12():653836. PubMed ID: 33897701
[No Abstract] [Full Text] [Related]
14. Identification of prognostic biomarkers and correlations with immune infiltrates among cGAS-STING in hepatocellular carcinoma.
Qi Z; Yan F; Chen D; Xing W; Li Q; Zeng W; Bi B; Xie J
Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 33006365
[TBL] [Abstract][Full Text] [Related]
15. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
Luo Y; Liu H; Fu H; Ding GS; Teng F
Front Immunol; 2022; 13():974377. PubMed ID: 36458010
[TBL] [Abstract][Full Text] [Related]
16. A gene-based risk score model for predicting recurrence-free survival in patients with hepatocellular carcinoma.
Wang W; Wang L; Xie X; Yan Y; Li Y; Lu Q
BMC Cancer; 2021 Jan; 21(1):6. PubMed ID: 33402113
[TBL] [Abstract][Full Text] [Related]
17. Identification of an m6A-Related Signature as Biomarker for Hepatocellular Carcinoma Prognosis and Correlates with Sorafenib and Anti-PD-1 Immunotherapy Treatment Response.
Jiang H; Ning G; Wang Y; Lv W
Dis Markers; 2021; 2021():5576683. PubMed ID: 34221187
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive analysis and validation of SNX7 as a novel biomarker for the diagnosis, prognosis, and prediction of chemotherapy and immunotherapy response in hepatocellular carcinoma.
Chen J; Gao G; Zhang Y; Dai P; Huang Y
BMC Cancer; 2023 Sep; 23(1):899. PubMed ID: 37743471
[TBL] [Abstract][Full Text] [Related]
19. Identification and validation of a novel predictive signature based on hepatocyte-specific genes in hepatocellular carcinoma by integrated analysis of single-cell and bulk RNA sequencing.
He Y; Qi W; Xie X; Jiang H
BMC Med Genomics; 2024 Apr; 17(1):103. PubMed ID: 38654290
[TBL] [Abstract][Full Text] [Related]
20. Construction and Validation of a Prognostic Gene-Based Model for Overall Survival Prediction in Hepatocellular Carcinoma Using an Integrated Statistical and Bioinformatic Approach.
Dessie EY; Tu SJ; Chiang HS; Tsai JJP; Chang YS; Chang JG; Ng KL
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33562824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
